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Chronic kidney disease (CKD) is a public health epidemic that
affects millions of people worldwide. Presence of CKD
predisposes individuals to high risks of end-stage renal
disease (ESRD), cardiovascular disease, and premature death.
Disordered phosphate homeostasis with elevated circulating
levels of fibroblast growth factor 23 (FGF23) is an early and
pervasive complication of CKD. CKD is likely the most
common cause of chronically elevated FGF23 levels, and the
clinical condition in which levels are most markedly elevated.
Although increases in FGF23 levels help maintain serum
phosphate in the normal range in CKD, prospective studies in
populations of pre-dialysis CKD, incident and prevalent ESRD,
and kidney transplant recipients demonstrate that elevated
FGF23 levels are independently associated with progression
of CKD and development of cardiovascular events and
mortality. It was originally thought that these observations
were driven by elevated FGF23 levels acting as a highly
sensitive biomarker of toxicity due to phosphate. However,
FGF23 itself has now been shown to mediate ‘off-target,’
direct, end-organ toxicity in the heart, which suggests that
elevated FGF23 levels may be a novel mechanism of adverse
outcomes in CKD. This report reviews recent advances in
FGF23 biology relevant to CKD, the classical effects of FGF23
on mineral homeostasis, and the studies that established
FGF23 excess as a biomarker and novel mechanism of
cardiovascular disease. The report concludes with a critical
review of the effects of different therapeutic strategies
targeting FGF23 reduction and how these might be
leveraged in a future randomized trial aimed at improving
outcomes in CKD.
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BRIEF OVERVIEW OF FIBROBLAST GROWTH FACTOR 23 AND
ITS EFFECTS ON MINERAL METABOLISM
Fibroblast growth factor 23 (FGF23) is an endocrine
hormone that is secreted by osteocytes and osteoblasts.1–3
The classical effects of FGF23 in the kidney and parathyroid
glands are mediated by its binding to FGF receptors (FGFRs)
complexed to the co-receptor klotho, which increases the
binding affinity of FGF23 for FGFR.4 The primary physio-
logical actions of FGF23 are to stimulate phosphaturia by
downregulating luminal expression of sodium–phosphate co-
transporters in the proximal tubule;5 to reduce systemic levels
of 1,25-dihydroxyvitamin D by directly inhibiting the renal 1-
a hydroxylase and stimulating the catabolic 24-hydroxylase;6
and to inhibit parathyroid hormone (PTH) secretion.7 For a
more detailed review of the molecular biology of FGF23 and
klotho, the reader should refer to recent comprehensive
reviews.8–15
REGULATION OF FGF23 SECRETION IN HEALTH
Role of dietary and serum phosphate
Healthy individuals are able to maintain their serum
phosphate in a relatively narrow range regardless of dietary
phosphate intake, in part, because FGF23 levels rise and fall
in parallel with the amount of dietary phosphate. High FGF23
levels in response to high phosphate intake induce greater
urinary fractional excretion of phosphate, and, by lowering
1,25-dihydroxyvitamin D levels, reduce the efficiency of
phosphate absorption in the gut. When phosphate intake is
low, FGF23 levels fall, renal phosphate reabsorption increases,
and the efficiency of phosphate absorption in the gut is
enhanced by the resulting increase in 1,25-dihydroxyvitamin
D levels. These observations were largely derived from small
interventional feeding studies in healthy humans.16–18 A
recent study of 1261 physicians in the Health Professionals
Follow-up Study was the first to confirm a direct correlation
between phosphate intake and FGF23 levels at the population
level.19 Although the absolute effect size was modest, this
finding is noteworthy given the imprecise ascertainment of
dietary phosphate in nutritional epidemiology studies.20
Although it is often assumed that high levels of
serum phosphate stimulate FGF23 secretion directly, clear
corroborating evidence is lacking. Indeed, changes in
serum phosphate did not precede changes in FGF23 in the
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phosphate feeding studies,16–18 and when serum phosphate
was raised through non-dietary approaches, FGF23 levels did
not change.21,22 Furthermore, cultured osteoblasts increase
FGF23 expression in response to 1,25-dihydroxyvitamin D
and PTH23 but not phosphate.24 Thus, a critical question
remains unanswered: Exactly what is FGF23 actually regulat-
ing? If it is primarily phosphate balance, how is this sensed if
not via changes in serum phosphate levels? It is important
to note that feeding studies found that the responsiveness
of FGF23 to dietary phosphate is sluggish (hours to days)
compared with the exquisite sensitivity of PTH to subtle
changes in calcium homeostasis (seconds to minutes).25–27
Deciphering the physiological and molecular basis of this
difference could shed light on the search for the highly
sought after phosphate-sensing apparatus.
Role of vitamin D
In a classic negative endocrine feedback loop, 1,25-dihydroxy-
vitamin D stimulates FGF23 secretion, and FGF23 lowers
levels of 1,25-dihydroxyvitamin D.8 The regulation of FGF23
transcription is controlled by a vitamin D response element
in the FGF23 promoter,24 such that some vitamin D activity
is essential for FGF23 production. This is supported by the
finding of undetectable FGF23 levels in vitamin D receptor–-
ablated mice, even after dietary phosphate loading,28 and in
1-a hydroxylase–ablated mice.29 Further support for a
gatekeeper effect of vitamin D on FGF23 expression can be
inferred from the finding that FGF23 levels were also
undetectable when 1-a hydroxylase ablation was super-
imposed on klotho-ablation,29 which alone causes markedly
elevated FGF23 levels.4 Although the biochemical picture in
the double mutants is somewhat clouded by hypophos-
phatemia and hypocalcemia, which may lower FGF23, these
changes are unlikely to fully account for undetectable FGF23
in this model.29
Role of PTH
FGF23 and PTH also share a negative endocrine feedback
loop. FGF23 inhibits PTH secretion via an FGFR-klotho-
dependent pathway,7 and PTH stimulates FGF23 both
directly and indirectly via PTH-mediated increases in 1,25-
dihydroxyvitamin D.23,30–32 In vitro, animal and human data
demonstrated the direct effect of PTH: FGF23 expression
increased in an osteoblast cell line in response to PTH23
(although not in all studies24); expression of a constitutively
active PTH receptor in osteocytes increased FGF23 produc-
tion;32 parathyroidectomy prevented and rescued elevated
FGF23 levels in an adenine model of chronic kidney disease
(CKD) independent of 1,25-dihydroxyvitamin D and cal-
cium;23 and, in hemodialysis patients administered intrave-
nous PTH, FGF23 levels rose in the setting of no increase in
1,25-dihydroxyvitamin D.31 Although results from these
models are convincing, biochemical analysis of patients with
primary hypoparathyroidism and their response to therapy
reveals the complexity of the integrated physiology. In the
absence of PTH, FGF23 levels are elevated33 rather than
severely depressed, as would be expected if PTH was essential
for increased FGF23 secretion in humans. However, persistent
hyperphosphatemia in untreated hypoparathyroidism sug-
gests that FGF23 levels are either ineffective or inappropriately
low, perhaps because of the lack of PTH or the low levels of
1,25-dihydroxyvitamin D and serum calcium it causes.33
Indeed, after treatment with calcitriol, FGF23 increases and,
despite the tendency of vitamin D to augment phosphate
absorption in the gut, serum phosphate decreases rapidly
toward normal, albeit incompletely.34,35 This emphasizes that
dynamic changes in FGF23 expression can occur in the
absence of PTH, and FGF23 can induce phosphaturia in the
absence of PTH, but that both FGF23 and PTH are needed to
maintain completely normal serum phosphate levels.
Role of calcium
Although less well appreciated than other regulators, higher
serum calcium also stimulates FGF23 secretion.28,36 When
wild-type mice were treated with a high calcium diet that
led to increased serum calcium, FGF23 levels rose.28 PTH
and 1,25-dihydroxyvitamin D levels were not reported but
undoubtedly decreased because of hypercalcemia. This
supports a direct effect of calcium given that the other main
stimuli of FGF23 decreased or were unchanged. In the same
classic study by Shimada et al.,28 a similar response was
observed in vitamin D receptor–ablated mice, which is
especially noteworthy because hypercalcemia induced an
increase in otherwise undetectable FGF23 levels, but a high
phosphate diet—the classic FGF23 stimulus—did not.
Finally, elevated FGF23 levels have been reported in
hypercalcemia of malignancy when PTH is suppressed.37,38
Although proof of a putative endocrine feedback loop awaits
data on the effects of hypocalcemia, the finding that calcium
loading directly stimulates FGF23 secretion may be highly
relevant to the therapeutic management of phosphate
homeostasis in CKD (reviewed below).
Roles of iron and iron deficiency
Intravenous iron can induce an acute osteomalacia syndrome
in non-CKD patients due to increased FGF23 secretion.39,40
FGF23 levels also increased in response to intravenous iron in
patients with end-stage renal disease (ESRD) undergoing
hemodialysis, but the magnitude of change was small.41 More
recent data suggest that iron deficiency may stimulate FGF23
transcription.42,43 In healthy individuals and wild-type mice,
lower serum iron concentrations correlated with elevated
FGF23 levels measured with a C-terminal (cFGF23) but not
an intact (iFGF23) assay.42,43 This suggests that iron
deficiency stimulates FGF23 synthesis but may not lead to
increased circulating levels of biologically active hormone,
perhaps because it is cleaved by furin within osteocytes into
fragments,44 which are released and can be detected with the
C-terminal assay. In the setting of autosomal dominant
hypophosphatemic rickets, in which an FGF23 mutation
renders it resistant to cleavage, increased FGF23 transcription
due to iron deficiency induces an increase in intact FGF23
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levels, which results in hypophosphatemia.42,43 Further
studies are needed to determine whether iron stores between
the extremes of severe deficiency and high-dose infusion
contribute to basal FGF23 levels in CKD.
FGF23 LEVELS IN CKD
Several cross-sectional studies demonstrated that FGF23
levels are elevated in CKD compared with healthy individuals
(Figure 1).25,45,46 Similar results were observed in studies
that evaluated FGF23 in pediatric CKD populations.47,48
Although the exact CKD stage when FGF23 levels first
became significantly elevated differed across studies, higher
FGF23 on a continuous scale was consistently associated with
higher serum phosphate, higher fractional excretion of
phosphate, lower estimated glomerular filtration rate (eGFR),
and lower levels of 1,25-dihydroxyvitamin D, independent of
eGFR.25,45,46 The latter suggested that inhibition by FGF23,
rather than insufficient renal mass, was the primary
mechanism of reduced 1,25-dihydroxyvitamin D levels in
progressive CKD. This was confirmed in animal studies, in
which administration of neutralizing anti-FGF23 antibodies
fully normalized 1,25-dihydroxyvitamin D levels without
altering the severity of CKD (and despite lowering PTH).49
This elegant study suggested that secondary hyperparathyr-
oidism in CKD results from increased FGF23 leading to
reduced 1,25-dihydroxyvitamin D, which releases the para-
thyroid glands from feedback inhibition by decreasing
vitamin D receptor activation, and contributing to subtle
hypocalcemia that chronically stimulates PTH.50
This pathophysiological sequence is supported by an
analysis of mineral metabolites in 3879 participants with
CKD stages 2–4 in the prospective Chronic Renal Insuffi-
ciency Cohort (CRIC) study.51 C-terminal, FGF23 levels were
elevated in many stage 2 and most stage 3–4 patients, and an
elevated FGF23 level was more prevalent than elevated PTH
or serum phosphate at all levels of eGFR.52 Although the
greater prevalence of elevated FGF23 levels versus PTH or
phosphate in strata of more preserved eGFR was suggestive of
‘earlier’ onset of FGF23 excess, this inference was based on a
‘pseudo-longitudinal’ interpretation of cross-sectional data in
which eGFR served as a surrogate of time. Conclusively
defining the pathophysiological sequence of secondary
hyperparathyroidism in human CKD will require serial
evaluations over time within individual CKD patients,
which has never been done for FGF23 or for other
mineral metabolites, despite years of intense investigation.
However, even those studies will need to be interpreted
with caution because attempting to parse which mineral
metabolite is deranged first as defined by being above a
somewhat artificial cut point oversimplifies the intricacies
underlying the integrated pathophysiology. Nevertheless, for
the practicing clinician and the clinical trialist defining
entry criteria, these data suggest that FGF23 is superior to
existing markers as a sensitive screening test to identify which
patients are developing disordered mineral metabolism in
early CKD.
In patients with ESRD undergoing dialysis, FGF23 rises
over time and often reaches levels that are 41000-fold above
normal (Figure 1);53,54 this renders ESRD the clinical setting
in which the highest levels of FGF23 have been reported.
Although some studies suggest that inactive C-terminal
fragments of FGF23 accumulate in ESRD,55 and others report
that virtually all circulating FGF23 is biologically intact,56
analyses using intact assays confirm markedly elevated
levels.54,56–58 This is likely due to a combination of increased
bone production of FGF233 and decreased degradation, but
clearance by the kidney or dialysis does not appear to
contribute meaningfully to the circulating level.53 Indeed, the
mechanisms of how FGF23 is removed from the circulation,
and where and how it is degraded remain unknown.
FGF23 levels decline rapidly following kidney transplanta-
tion in most patients with prompt allograft function,
however, persistently elevated FGF23 levels in the very
early-post-transplant period contribute to post-transplant
hypophosphatemia (Figure 1).59–62 By 1 year post-transplant,
FGF23 levels are significantly reduced (Figure 1) but PTH
often remains elevated.61 Thus, the modest but persistent
reductions in serum phosphate levels in the late post-
transplant period are more likely related to hyperparathy-
roidism. Perhaps PTH-mediated renal phosphate wasting in
kidney transplant recipients,63 who are known to experience
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Figure 1 |Representative levels of fibroblast growth factor 23
(FGF23) in health, various states of chronic kidney disease
(CKD; orange bars), and in primary hypophosphatemic
disorders (blue bars). The dual y axis presents FGF23 levels on
the scales of the two commercially available assay platforms. The
intact assay detects biologically intact FGF23 exclusively (iFGF23),
whereas the C terminus (cFGF23) assay is capable of detecting
both the intact molecule and its C-terminal fragments.148 The gray
area represents the presumed but incompletely defined normal
ranges. ‘11 hypoP, FGF23’ refers to hypophosphatemic disorders
caused by primary FGF23 excess, for example, X-linked
hypophosphatemia.149 ‘11 hypoP, non-FGF23’ refers to
hypophosphatemic disorders caused by mechanisms other than
FGF23 excess, for example, hereditary hypophosphatemic rickets
with hypercalciuria, in which FGF23 levels are secondarily
suppressed.150,151 ESRD, end-stage renal disease; Tx,
transplantation.
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significant bone loss,64 induces total body phosphate
depletion that causes FGF23 levels to decrease, akin to
other FGF23-independent phosphate wasting syndromes
(Figure 1).65,66 Phosphate balance studies in stable kidney
transplant recipients with low phosphate and FGF23 levels
would be particularly important.
REGULATION OF FGF23 SECRETION IN CKD
Among the least well understood yet critically important
aspects of FGF23 biology is what drives levels up in early
CKD. It has been proposed that FGF23 rises as an appropriate
compensatory response to phosphate retention due to
impaired renal excretion or due to reduced renal expression
of klotho that induces resistance to FGF23. However, FGF23
levels are frequently elevated in early CKD, yet classic balance
studies found no evidence of positive phosphate balance even
in stage 5.67,68 Furthermore, among the 287 CRIC partici-
pants with eGFR 60–79 ml/min per 1.73 m2, median cFGF23
was already elevated and serum phosphate was actually
significantly lower than in participants with higher eGFR.52
This modest but statistically significant reduction in serum
phosphate was accompanied by elevated urinary fractional
excretion of phosphate, suggesting a mild degree of FGF23-
mediated phosphate wasting. A similar phosphate leak was
observed in young patients with CKD stage 1 due to
autosomal dominant polycystic kidney disease, who had
markedly higher FGF23 levels and lower serum phosphate
than healthy controls.69 Phosphate leaking is incompatible
with phosphate retention, and, as reduced klotho expression
should impair phosphate excretion,70 the lack of even a subtle
increase in serum phosphate in early CKD also argues against
the primacy of klotho deficiency. Indeed, in an animal model
of progressive CKD, significant increases in FGF23 levels
preceded significant reductions in klotho expression.71
These data suggest that early CKD may be a state of
primary FGF23 excess that reduces serum phosphate levels
and klotho expression. The latter could occur via FGF23-
mediated reductions in 1,25-dihydroxyvitamin D, which is
known to stimulate klotho expression.72–74 A plausible
hypothesis to explain primary FGF23 excess in early CKD
is a defect in the bone that somehow stimulates FGF23
secretion directly.75,76 Although bone production of FGF23
was not increased in a mouse model of CKD with elevated
serum levels,71 human bone biopsies demonstrated increased
FGF23 production beginning in CKD stage 2 and correlation
between osteocyte expression and circulating protein levels.3
If confirmed, this would focus further attention on the
osteocyte as a likely site of phosphate sensing. The reduced
degradation of FGF23 within osteocytes or after its secretion
could also contribute to early increases in circulating levels in
CKD.44 It is important to emphasize that even if reduced
klotho expression does not account for the initial increase in
FGF23 levels in CKD, progressive reduction of klotho
expression clearly has a critical role in CKD. In the
parathyroid glands, reduced klotho expression along with
reduced FGFR expression induces resistance to inhibition by
FGF23 that contributes to the coexistence of secondary
increases in both FGF23 and PTH in CKD.77–79 In addition,
klotho deficiency has been implicated in the pathogenesis of
vascular calcification,80 which is an important risk factor for
mortality in CKD.
FGF23 AND CLINICAL OUTCOMES IN CKD
Numerous reports have linked elevated FGF23 levels to the
main adverse clinical outcomes in CKD: progression to
ESRD, cardiovascular disease, and death.
FGF23 and mortality
End-stage renal disease. Elevated levels of FGF23 were
independently associated with greater risk of mortality in a
1:1, case–control study of 400 participants nested in a
prospective cohort of patients with incident ESRD.58 In
addition to the large, monotonic magnitude of effect, an
unexpected finding was that adjusting for a large array of
demographic characteristics and laboratory tests that are
known to influence survival on hemodialysis had almost
no impact compared with the unadjusted results. These
observations helped spawn the concept that elevated FGF23
level is not merely a sensitive biomarker of phosphate-
mediated cardiovascular toxicity, but perhaps it is directly
toxic itself.81 Although two studies revealed no association
of FGF23 with mortality,82,83 a study of 219 prevalent
hemodialysis patients confirmed that higher FGF23 levels
were independently associated with greater risk of mortality
in ESRD.84
Kidney transplant recipients. In a study of 984 prevalent
kidney transplant recipients with a median transplant vintage
at enrollment of 6 years, elevated FGF23 levels were
independently associated with greater subsequent risks of
mortality, allograft loss, and their composite.85 The results
were robust to whether FGF23 was modeled as a continuous
variable or in quantiles, and regardless of whether the analysis
focused on the entire population or the subgroup without
extremely low or high baseline eGFR. Furthermore, when
serum phosphate, PTH, and hemoglobin were substituted as
the primary exposure, neither was associated with outcomes.
This suggests a specific effect of FGF23 on mortality rather
than a general effect of impaired allograft function.
CKD stages 2–4. Two large studies analyzed FGF23 and
mortality in pre-dialysis CKD.86,87 In an analysis of 3879
participants in the CRIC study (mean eGFR 43±14 ml/min
per 1.73 m2) with median cFGF23 of 146 RU/ml (nearly three
times the normal range), there were 266 deaths during a
median follow-up of 3.5 years (20/1000 person-years).86
Elevated FGF23 levels were independently associated with
greater risk of mortality in unadjusted and fully adjusted
analyses (Figure 2). The large magnitude of effect was
homogenous across all strata of demographics, comorbid-
ities, eGFR, and laboratory tests, and only mildly attenuated
by multivariable adjustment. Among the mineral metabolites,
the risk of mortality was specific to FGF23 as PTH,
phosphate, fractional excretion of phosphate, and vitamin D
740 Kidney International (2012) 82, 737–747
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levels were not independently associated with mortality.
Furthermore, FGF23 was the strongest predictor of mortality
in the multivariable analyses, whereas the powerful effects of
the CKD-specific risk factors, proteinuria and low eGFR,
were abolished. These results suggest that elevated FGF23
levels mediate an important component of CKD-related risk
of death.
The second study was an analysis of 1099 participants in
the randomized Homocysteinemia in Kidney and End-Stage
Renal Disease (HOST) study with mean creatinine clearance
of 18±6 ml/min per 1.73 m2 at enrollment.87 The median
cFGF23 of 392 RU/ml was considerably higher than in the
CRIC study but consistent with this cohort’s more advanced
CKD. Similar to the results from CRIC, higher baseline
FGF23 levels were independently associated with increased
risk of mortality in a monotonic pattern with minimal
attenuation in sequentially adjusted multivariable models,
and FGF23 was the strongest predictor of mortality.
FGF23 and progression of CKD
Several published studies identified FGF23 as a risk factor for
CKD progression. In 177 patients with non-diabetic CKD,
higher levels of cFGF23 and iFGF23 were independently
associated with incident ESRD.88 A subsequent study of 55
diabetic CKD patients reported similar results, although the
small sample size that included only 12 ESRD events
precluded detailed multivariable analysis.89 In the CRIC
study, ESRD developed in 410 participants (33/1000 person-
years).86 Although the unadjusted association between
elevated FGF23 levels and greater risk of ESRD was
attenuated in multivariable analyses, the effect was signifi-
cantly modified by baseline eGFR. In fully adjusted stratified
analyses, higher cFGF23 was associated with ESRD in
participants with eGFR 430 ml/min per 1.73 m2, and the
magnitude of effect grew at more preserved levels of eGFR. In
contrast to CRIC, elevated cFGF23 was independently
associated with greater risk of ESRD in the HOST study of
CKD stage 4–5 patients.87 In aggregate, the data suggest that
elevated FGF23 level is a potentially important risk factor for
ESRD. Whether FGF23 is acting as a biomarker of cases of
CKD that are destined to progress most rapidly or it is a
direct mediator of disease progression requires further study.
FGF23 and cardiovascular disease events
Data on FGF23 and risk of cardiovascular events are less
developed. In 149 patients with mean eGFR of 36 ml/min per
1.73 m2, elevated cFGF23 was independently associated with
greater risk of the composite of myocardial infarction, stroke,
coronary, carotid or lower limb revascularization, lower
extremity amputation or death.90 In the HOST study,
elevated cFGF23 was strongly associated with increased risk
of the composite outcome of myocardial infarction, amputa-
tion, or stroke.87 Similar to the analysis of mortality in the
same study, there was minimal change in the point estimates
of risk after multivariable analysis, and FGF23 superseded all
classic cardiovascular risk factors to be the strongest predictor
of developing a cardiovascular event. When the individual
cardiovascular events were analyzed separately, the largest
hazard ratios were observed for amputation, followed by
myocardial infarction. FGF23 was not associated with stroke.
In an analysis of 833 participants in the Heart and Soul
Study that recruited predominantly non-CKD patients (22%
had eGFR o60 ml/min per 1.73 m2) with a history of
coronary artery disease, the median cFGF23 was relatively
normal (43 RU/ml), but those with higher levels had
independently increased risk of death and risk of developing
the composite of myocardial infarction, cerebrovascular event,
or hospitalization for congestive heart failure.91 The results
were driven by significantly greater rates of congestive heart
failure (n¼ 119) and cerebrovascular events (n¼ 36), as
FGF23 was not associated with risk of myocardial infarction
(n¼ 88). Although it is possible that the entry criterion of
established coronary artery disease could have biased the
analysis of myocardial infarction to the null, another well-
powered study of incident coronary artery disease in non-CKD
patients (n¼ 422 events) also revealed no link to FGF23.92
FGF23 and intermediate measures of cardiovascular risk
Several studies reported strong associations between FGF23
and cardiovascular risk factors. In 1261 participants in the
Health Professionals Follow-up Study, the vast majority of
whom had normal renal function, higher FGF23 levels were
independently associated with older age, hypertension,
obesity, and smoking.19 Although not their primary focus,
several studies of CKD patients similarly reported that higher
FGF23 levels were associated with diabetes, smoking, prior
cardiovascular disease, obesity, and higher levels of inflam-
matory markers.19,86,87,91,93–96
The endothelium and vessel wall are targets of injury in
CKD. Higher FGF23 levels were independently associated
with endothelial dysfunction, marked by lower flow-mediated
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vasodilatation of the brachial artery, in patients with CKD
stages 3–4 (ref. 97) and in an older, predominantly non-CKD
population.98 The data on FGF23 and vascular calcification
are murky with some studies reporting an independent
association99,100 and others reporting none.101,102 Small
sample sizes, differential approaches to adjusting for con-
founding, imaging of different arterial beds, and lack of
prospective data limit the conclusions that can be drawn from
this body of work. When contrasted with the consistent data
linking higher serum phosphate to more severe calcifica-
tion,103–108 these data suggest lack of a true effect of FGF23.
In contrast to vascular calcification, higher FGF23 is
consistently associated with left ventricular hypertrophy
(LVH), which is an important mechanism of congestive
heart failure and arrhythmia, and a potent risk factor for
mortality in CKD.109,110 Thus, LVH is one plausible
biological mechanism to explain the link between higher
FGF23 and greater risk of mortality. Several cross-sectional
studies in CKD, ESRD, and non-CKD populations demon-
strated that elevated FGF23 levels are independently asso-
ciated with greater left ventricular mass index and greater
prevalence of LVH.82,94,111–115 Elevated FGF23 levels were also
associated with reduced ejection fraction and prevalent atrial
fibrillation but not coronary artery disease in a cross-
sectional study of 885 study participants undergoing elective
coronary angiography, 19% of whom met criteria for CKD.94
The link between FGF23 and cardiac injury in CKD was
solidified by an echocardiography study of 3070 CRIC study
participants.116 In the cross-sectional component of the
analysis, higher cFGF23 levels were independently associated
with reduced ejection fraction, greater LVMI, and greater
prevalence of concentric and eccentric LVH. In the first
prospective analysis of FGF23 and risk of LVH, elevated
cFGF23 predicted new-onset LVH in CRIC participants who
had normal LV geometry at baseline and underwent repeat
echocardiography 3 years later.116 The risk of incident LVH
according to baseline FGF23 was magnified in the subgroup
of participants without hypertension. Presumably, eliminat-
ing this major confounder allowed the independent effects of
FGF23 to emerge more clearly.
‘OFF-TARGET’ TOXICITY OF FGF23
Lack of a consistently robust association between FGF23 and
coronary artery calcification or incident coronary events
argue against occlusive atherosclerotic events as the primary
link between FGF23 and death. Furthermore, progressive
ventricular failure, arrhythmia, and sudden death—compo-
nents of the incompletely understood uremic cardiomyo-
pathy117—are more common causes of death in advanced
CKD than acute myocardial infarction.118–120 Combined with
the consistent association between FGF23 and LVH, these
clinical clues focused the search for cardiovascular toxicity of
FGF23 on the myocardium.
In an in vitro experimental system that was previously
used to demonstrate the hypertrophic effects of FGF2,
escalating doses of FGF23 induced a dose-dependent increase
in the surface area of neonatal rat ventricular cardiac
myocytes and activated hypertrophic gene programs.116
Administration of a pan-FGFR inhibitor prevented FGF23-
mediated hypertrophy, indicating that the effect was
mediated by FGFRs, which are expressed on cardiac
myocytes. These results were confirmed in a series of
experiments in rodents.116 Injection of FGF23 into the left
ventricular myocardium or intravenously in wild-type mice
induced LVH. Most relevant to CKD, LVH in uremic rats that
manifest markedly elevated FGF23 levels was prevented by
treatment with a pan-FGFR inhibitor despite persistence of
equally severe hypertension as in the rats that were untreated.
These results confirmed the hypertension-independent effect
of FGF23 that was reported in the prospective analysis of
normotensive CRIC participants.116 An especially important
finding was that klotho was not detected in cardiac myocytes,
indicating that FGF23-mediated hypertrophy of cardiac
myocytes occurs independent of membrane-bound klotho.
The finding of LVH in klotho heterozygous mice that had
moderately elevated FGF23 levels (threefold above normal),
and more severe LVH in klotho-ablated mice that had
markedly elevated FGF23 levels (415-fold above normal)
excluded the possibility that the soluble form of klotho is
needed for LVH to develop in states of elevated FGF23 levels.
These results established the concept of klotho-independent,
direct end-organ toxicity of FGF23, and a potentially
prominent role of FGF23 in the pathogenesis of uremic
cardiomyopathy. They also establish a precedent for future
investigations to either confirm or refute whether direct
effects of FGF23 underlie other epidemiological associations,
for example, with arterial calcification, atherosclerosis,
inflammation, and CKD progression.
THERAPEUTIC STRATEGIES TO LOWER FGF23 LEVELS
If elevated FGF23 levels are mechanistically linked to
increased risk of death in CKD, therapeutic strategies to
reduce levels could lead to improved survival. Several
approaches have been proposed.
Diet
In non-CKD patients, reducing dietary phosphate intake
lowers FGF23 levels.16–18 By comparison, data in CKD are
scarce. Although the randomized assignment of a 750-mg
phosphate diet did not lower FGF23 levels in a small pilot
study, the 1500 mg diet raised FGF23 levels in several
participants,121 suggesting that dietary phosphate intake does
indeed contribute to dynamic changes in FGF23 levels in
CKD. A cross-over study that compared the impact of a
meat-based versus a vegetarian-based diet on FGF23 levels in
nine CKD patients with mean eGFR of 32 ml/min per 1.73 m2
confirmed an important effect of diet.122 The total phosphate
contents of the diets were identical but because of lower
bioavailability of phosphate in plants compared with
meat,20,123 less phosphate was absorbed in the vegetarian
phase as indicated by lower urinary phosphate excretion.
Consistent with reduced phosphate absorption, consumption
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of the vegetarian diet significantly lowered serum phosphate
and FGF23 levels. Similar results were observed in animals.124
Although these studies emphasized the role of phosphate
bioavailability over absolute phosphate intake and did not
analyze the effects of a phosphate additive–enriched diet that
would have an even higher bioavailability of phosphate,20,123
they demonstrate that dietary manipulation can lower FGF23
levels significantly in CKD.
Phosphate binders
In addition to reducing total phosphate in the diet or
manipulating its bioavailability profile, phosphate binders
can be used to reduce absorption in the gut. Several studies
reported that administration of the phosphate binders,
lanthanum, sevelamer, and aluminum–magnesium, lowered
FGF23 levels in healthy volunteers, hyperphosphatemic ESRD
patients, and CKD patients with normal or elevated serum
phosphate.17,125–128 Although another randomized study of
CKD stage 3–4 patients found no reduction in FGF23 levels
in participants treated with lanthanum versus placebo, the
study duration was only 2 weeks,121 which may have been
inadequate given that previous studies reported no change in
FGF23 at 2 weeks but significant 22–45% reductions after 4–6
weeks of treatment with lanthanum127 or sevelamer.126
Certain studies compared the effects on FGF23 of specific
phosphate binders. In the first, sevelamer, but not calcium
acetate, lowered FGF23 levels over a 6-week duration of
intervention in CKD stage 3–4 patients with normal serum
phosphate levels.126 The second study randomized 100
hyperphosphatemic stage 4 patients to sevelamer or calcium
acetate.128 Although each intervention lowered serum
phosphate, sevelamer but not calcium significantly lowered
FGF23 and significantly improved endothelial function.
Although the results are provocative, several unusual
biochemical findings characterized the study population.
Despite a mean eGFR of 23 ml/min per 1.73 m2, participants
had markedly elevated mean serum phosphate of 7.7 mg/dl,
which is quite uncommon for a non-ESRD population. Even
more unexpected was their mean iFGF23 of 40 pg/ml, which
was disproportionately low for the degree of hyperphos-
phatemia and severity of CKD. Nevertheless, this study is
important for two reasons. It established that a therapeutic
intervention targeting phosphate homeostasis is capable of
improving a meaningful intermediate measure of cardiovas-
cular risk in CKD patients. Although the decrement in FGF23
but not serum phosphate was independently associated with
the improvement in endothelial function, it will be important
to determine if improvements in endothelial function will
also occur when FGF23 is reduced in CKD patients with
normal serum phosphate.
Second, this study validated the previous finding that non-
calcium-based phosphate binders reduce FGF23 more
effectively than calcium-containing binders despite compar-
able effects on serum phosphate. Stimulation of FGF23
secretion by calcium likely offset the FGF23-lowering effect
that would be expected by its phosphate binding. These
results highlight the need for additional head-to-head trials
of specific phosphate binders, with and without active
vitamin D therapy, and utilizing different dietary strategies
for prolonged durations of follow-up. Data from such studies
are needed to further crystallize the optimal approach to
FGF23 reduction that should be carried forward to a future
placebo-controlled randomized trial of hard clinical out-
comes in CKD stages 3–4.129
Cinacalcet
Animal and human studies suggest that cinacalcet lowers
FGF23 levels in the setting of CKD.130–132 The incompletely
elucidated mechanisms are likely multifactorial and may vary
by stage. In models of pre-dialysis CKD, cinacalcet lowers
FGF23 in addition to PTH leading to an increase in serum
phosphate,132 but in ESRD, cinacalcet lowers FGF23 and
PTH in association with a reduction in serum phosphate.131
This suggests that cinacalcet’s effect on FGF23 is not
mediated by changes in serum phosphate. Reduced 1,25-
dihydroxyvitamin D due to cinacalcet-mediated reductions
in PTH could contribute to reduced FGF23 when there is
residual renal function,132 but is probably not as important
in ESRD, when 1,25-dihydroxyvitamin D levels are already
severely depressed.133 A likely mechanism of how cinacalcet
reduces FGF23 is via reduced PTH, which is a universal effect
of cinacalcet across all stages of CKD.134,135 Although reduced
serum calcium is another universal effect of cinacalcet that
might theoretically contribute to reduced FGF23 levels, a
putative effect of hypocalcemia seems less likely because the
calcium-sensing receptor actually ‘senses’ hypercalcemia in
the presence of calcimimetics.
Vitamin D
As expected based on the known physiology, animal and
human studies demonstrate that active vitamin D raises
FGF23 levels, without significant differences between specific
preparations.132,136,137 These findings present an apparent
paradox at the intersection of FGF23 research and epidemio-
logical studies of active vitamin D and clinical outcomes:
Elevated FGF23 levels are associated with accelerated
mortality, yet active vitamin D therapy, which raises FGF23,
is associated with longer survival.138–143 The highly variable
FGF23 response to active vitamin D therapy between
individuals—from minimal to large increases—in all popula-
tions, including children with ESRD, adults with CKD stages
3–4, adults undergoing hemodialysis, and uremic rats,
provides important insight into this potential contradic-
tion.132,136,137,144 Although a higher baseline FGF23 is a risk
factor for mortality, vitamin D–treated patients who experi-
ence prolonged survival on dialysis may be those who exhibit
a modest FGF23 response to treatment, whereas those who die
early despite receiving therapy may be the ones who exhibit a
greater increase in FGF23 (Figure 3). Studies that help clarify
the interaction between FGF23 and active vitamin D will be
crucial for designing integrated, evidence-based approaches
for treating mineral metabolism in CKD and ESRD.
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Other approaches
The finding that elevated FGF23 level directly induces cardiac
injury might suggest a potential utility in CKD of neutraliz-
ing FGF23 with antibodies that are under development for
the treatment of syndromes of primary FGF23 excess, such as
X-linked hypophosphatemia.145 However, use of anti-FGF23
antibodies that were specifically designed to prevent phos-
phate wasting caused by FGF23 could be dangerous in CKD
because they would induce or exacerbate hyperphosphate-
mia49 and perhaps hypercalcemia due to increases in 1,25-
dihydroxyvitamin D, as shown in FGF23-ablated mice.146
Alternatively, novel antibodies could be raised against the
FGFR that mediates the cardiac toxicity of FGF23 but do not
interfere with binding to renal FGFR-klotho, thereby
retaining the phosphaturic effects of FGF23 that are desirable
in CKD. Assessing the feasibility of this approach will require
detailed understanding of the cardiac FGFRs that underlie
FGF23-mediated LVH and the physical–chemical aspects of
their interaction with FGF23 relative to FGFR in the kidney.
CONCLUSIONS
Recurring themes in the research of FGF23 and mortality
include consistency of results within specific study populations
(one CKD study vs. another), consistency between study
populations (CKD, dialysis, and post-transplant), large
monotonic magnitudes of effect in prospective studies,
minimal confounding, and independence from and specificity
relative to other mineral metabolites. Enumerated on this list
are several of the Hill criteria that suggest causality.147
Translational data support a causal role for FGF23 in the
pathogenesis of LVH, which is a leading pattern of
cardiovascular injury in CKD that is strongly associated with
death. Although in its infancy, an emerging body of work
suggests promising approaches to reduce FGF23 levels. At the
end of the long and winding scientific tunnel ahead lies hope
that a randomized trial will leverage the last decade’s data on
FGF23 and culminate in a meaningful improvement in clinical
outcomes for CKD patients of the future.
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